KalVista Pharmaceuticals disclosed FDA postponement of its regulatory decision for an oral on-demand hereditary angioedema treatment, attributing the delay to the agency’s heavy workload and limited resources. This delay impacts KalVista’s clinical development timeline for the promising therapy, which could provide a novel oral option for hereditary angioedema patients.